SCHEMBL4133488

SCHEMBL4133488

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C\c3cccn3-c3ccc(Br)cc3)S2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
TDP1 Q9NUW8 6/20 0.38
BLM P54132 3/20 0.38
KEAP1 Q14145 2/20 0.38
NFE2L2 Q16236 2/20 0.38
SAE1 Q9UBE0 2/20 0.38
UBA2 Q9UBT2 2/20 0.38
HTT P42858 1/20 0.37
POLB P06746 6/20 0.36
GRK2 P25098 3/20 0.36
MCL1 Q07820 2/20 0.36
DNMT1 P26358 1/20 0.36
DUSP3 P51452 2/20 0.36
DUSP22 Q9NRW4 1/20 0.36
PKM P14618 2/20 0.36
CTDSP1 Q9GZU7 3/20 0.35
APEX1 P27695 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133496 1.00 MAPT (0.43) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL4129351 0.92 MAPT (0.41) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL4129359 0.92 MAPT (0.41) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL4123871 0.79 POLB (0.51) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL4123875 0.79 POLB (0.51) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL4133862 0.77 DUSP22 (0.49) ALDH1A1POLBDUSP3DUSP22GFER
SCHEMBL4133860 0.77 DUSP22 (0.49) ALDH1A1POLBDUSP3DUSP22GFER
SCHEMBL4138121 0.76 NSD2 (0.43) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL4138118 0.76 NSD2 (0.43) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL4132445 0.74 FFAR1 (0.47) HTTDUSP3DUSP22LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MAPT 3532/4885ALDH1A1 216/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.